Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Delivers Update to CDS Customers with Assembled, Annotated Mouse Genome and New Human Assembly with Sequence, Annotation Tracking
Offers Subscribers Advantages in Comparative Genomics, Disease Gene Association

Rockville, MD - September 27, 2001

Celera Genomics (NYSE: CRA), an Applera Corporation business, today announced the delivery to customers of the assembled and annotated mouse genome together with an updated assembly of the human genome with sequence and annotation tracking. These enhanced products are exclusively available through the Celera Discovery System™, a bioinformatics platform that scientists can leverage target identification, validation and prioritization. Celera currently has more than 100 subscribers comprising pharmaceutical and biotechnology companies as well as academic institutions.

Comparative Genomics Capability
Celera offers customers unique comparative genomics capabilities with the only available assembled and annotated mouse genome and the latest version of the human genome assembly. Celera sequenced the 129X1/SvJ, DBA/2J, and A/J strains of mouse and has approximately 5.3-fold coverage of the mouse genome, ensuring greater than 99 percent representation of the mouse genome. Celera announced the first assembly of the human genome in June 2000 and has continued to refine and validate its assembly since then. Celera has now delivered to customers an improved version of the human assembly. This assembly represents 97% of the human genome in segments of at least 100,000 base pairs and 92% in segments of at least one million base pairs, allowing for more accurate gene prediction. The availability of these two genomes has enabled Celera scientists to provide customers with accurate gene predictions and annotation.

“These newly assembled and annotated genomes represent significant improvements in the quality and quantity of genomic data that are now available to researchers worldwide,” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “The ability to compare the mouse genome and our advanced version of the human genome using CDS should allow researchers to make important discoveries in the regulation of human genes based on conserved gene structure, including DNA regulatory sequences outside of the protein-coding regions that are shared with mouse genes.”

Sequence and Annotation Tracking
Celera offers a stable platform to support on-going research efforts by providing the reference standard, the Celera Human Reference Genome. Scientists and bioinformatics experts can utilize the genome as a platform upon which to map and view discovery data. In the updated and improved assembly, the previous mapping of features are conveniently maintained using a combination of computational and hand curated methods. The result is time saving and accurate presentation of the data.

Benefits to Customers
Access to assembled and annotated genomes and the bioinformatics tools with which to mine this data is becoming crucial to research programs in both commercial and academic research settings. The Celera Discovery System enables opportunities in target discovery, prioritization and validation through the following:

  • Better understanding of gene function and disease process in humans through new avenues of research into the mechanisms of gene conservation and regulation. Celera estimates there are approximately the same numbers of genes in the mouse as in the human. Initial comparisons of the mouse and human genomes by Celera already identified more than 16,000 genes that correspond in mouse and human. Of those nearly 4,000 appear to be related to human disease.

  • Improved mouse knock-out and knock-in experiments for more rapid design of targeting vectors and development of animal models for target validation using human and mouse conserved gene regions.

  • Accurate mapping of peptide sequences to genes for drug target searches.

  • Enhanced interpretation of gene expression information including tag and micro-array-based drug target analysis.

The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, and the genomic and biological data to advance the discovery process for researchers worldwide.

For more information on the Celera Assembled and Annotated Mouse and Human Genome products visit Celera’s web site at

About Celera
Applera Corporation comprises two operating groups. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation diagnostic and therapeutic discovery company. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for subscribers and for its own internal product development. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2000. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at, or by telephoning 800.762.6923.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.